Skip to main content

Avenue Therapeutics, Inc.

corporate_fare Company Profile

Avenue Therapeutics, Inc.

ATXI·OTC·Life Sciences·CIK 0001644963

Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing treatments for neurologic diseases. The company's current product candidates include ATX-04 and intravenous tramadol (IV tramadol). ATX-04 is a selective β2-adrenergic agonist for Pompe disease. In February 2026, Avenue entered into an exclusive license agreement with Duke University for patents and know-how related to clenbuterol, also referred to as ATX-04, for lysosomal storage diseases with a focus on Pompe disease. IV tramadol is a schedule IV opioid intended for the treatment of post-operative acute pain, which Avenue has been developing since its inception and prior to its initial public offering in 2017. Previously, through November 5, 2025, Avenue was involved with BAER-101 for the treatment of epilepsy and panic disorders. In November 2022, Avenue completed a Stock Contribution Agreement, dated May 11, 2022, with Fortress Biotech, Inc. to acquire shares in Baergic Bio, Inc., which was developing BAER-101. As a result, Baergic became a majority-controlled and owned subsidiary of Avenue. On November 5, 2025, Avenue announced an agreement for Baergic to be acquired by Axsome Therapeutics, Inc., including the global rights to BAER-101 (also known as AZD7325), a novel oral GABAA α2,3 subtype-selective receptor positive allosteric modulator (PAM). BAER-101 was originally licensed by Baergic from AstraZeneca AB and will be referred to as AXS-17 by Axsome. Avenue and other former stockholders of Baergic are eligible to receive additional payments and royalties from Axsome based on development, regulatory, and commercial milestones and net sales. Avenue Therapeutics, Inc. is a majority-controlled subsidiary of Fortress Biotech, Inc.

Avenue Therapeutics, Inc. (OTC:ATXI) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 5 items for ATXI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-06, rated 8/10. Across its 5 most recent items scored 7 or higher, the top rating is 9/10, with 4 rated 8 or above. Recent SEC coverage for ATXI spans 10-Q, 8-K, SCHEDULE 13D/A.

Recent high-impact activity:

  • Avenue Therapeutics Q3: Cash Down to $1.5M, Going Concern Reaffirmed
  • Avenue Therapeutics Reiterates Going Concern Warning as Cash Drops to $1.9M
  • Avenue Therapeutics Discloses Going Concern, Limited Cash Runway, and Inability to Access Capital Markets
  • Avenue Therapeutics Licenses ATX-04 for Pompe Disease, Bolstering Rare Disease Pipeline
  • Fortress Biotech Increases Stake in Avenue Therapeutics to 13.4% via Annual Equity Grant

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$1.4M
Net Income
-$2.91M
Op. Cash Flow
-$1.83M
Operating Income
-$3.08M
Cash & Equivalents
$2.85M
Debt / Equity
0.00×
Net Margin
-207.2%
Shares Outstanding
3.18M sh
Source: 10-K · filed 2026-03-30 · accession 0001437749-26-010359

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 1 shares in ATXI as of the October 30, 2026 settlement, unchanged from the prior period — about 1.0 days to cover at its recent average daily volume. On November 18, 2026, 0.5% of ATXI volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1 shares as of October 30, 2026
Change vs prior period 0.0%
Days to cover1.00 at avg daily volume of 3,420
Daily short volume (FINRA facilities)0.5% of 2,746 shares on November 18, 2026
5-day average short volume44.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with A →
$0.30
52-week range · as of 2026-11-06 $0.15 – $0.9699
Market cap
$988.49K
Volume
1.1K (0.2× avg)
3-mo avg 6.9K
Live data · 2026-11-21 21:50 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ATXI - Latest Insights

ATXI
Nov 06, 2026, 4:05 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.4289
Real-time Price: $0.300 info
Change: -$0.1289 (-30%) info
Market Cap: $988.49K info
ATXI
Aug 06, 2026, 5:35 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.3005
Real-time Price: $0.300 info
Change: -$0.0005 (-0.17%) info
Market Cap: $988.49K info
ATXI
May 08, 2026, 8:32 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.5502
Real-time Price: $0.300 info
Change: -$0.2502 (-45%) info
Market Cap: $988.49K info
ATXI
Feb 23, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.280
Real-time Price: $0.300 info
Change: +$0.020 (+7%) info
Market Cap: $988.49K info
ATXI
Jan 06, 2026, 4:11 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $0.620
Real-time Price: $0.300 info
Change: -$0.320 (-52%) info
Market Cap: $988.49K info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets